Biohaven EBITDA Margin 2016-2023 | BHVN
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Biohaven (BHVN) over the last 10 years. The current EBITDA margin for Biohaven as of March 31, 2023 is .
| Biohaven EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2021-06-30 |
$0.16B |
$-0.17B |
-111.61% |
| 2021-03-31 |
$0.07B |
$-0.17B |
-230.56% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.414B |
$0.463B |
|
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
|
